F18.159 Inhalant abuse with inhalant-induced psychotic disorder, unspecified

Name of the Condition

• Common Name: Inhalant Abuse with Inhalant-Induced Psychotic Disorder, Unspecified
• Medical Term: Inhalant Abuse with Inhalant-Induced Psychotic Disorder, Unspecified

Summary

Inhalant abuse with inhalant-induced psychotic disorder, unspecified involves the intentional misuse of inhalants—substances that produce chemical vapors—to achieve psychoactive effects, accompanied by the development of psychotic symptoms not further specified. This condition combines substance-related misuse with psychotic features, such as delusions or hallucinations, directly attributable to inhalant use. It can lead to acute intoxication, dependence, and significant physical or psychological harm, impacting an individual's health and daily functioning.

Causes

Inhalant abuse is primarily driven by the repeated misuse of inhalants for their psychoactive effects. Inhalants are often everyday household or industrial products, such as glue, paint thinners, aerosols, or solvents. The misuse of these substances can lead to dependence and, in some cases, induce psychotic symptoms due to their neurotoxic effects on the central nervous system.

Risk Factors

• Adolescents and young adults are more likely to experiment with inhalants.
• Individuals with a history of substance abuse or mental health disorders.
• Accessibility to inhalant products.
• Lack of proper supervision or guidance.

Symptoms

• Intense cravings or compulsive use of inhalants.
• Psychotic symptoms (e.g., delusions, hallucinations) directly linked to inhalant use.
• Impaired judgment or decision-making.
• Mood changes, such as agitation or paranoia.
• Physical signs of inhalant use, including chemical odors on breath or clothing.

Diagnosis

Diagnosis involves a comprehensive evaluation of the patient's history, including substance use patterns and psychotic symptoms. Clinical assessment focuses on confirming inhalant misuse and establishing a direct causal link between inhalant use and psychotic features. Laboratory tests may be used to detect inhalant exposure, and psychiatric evaluation helps rule out other conditions. Documentation must specify the presence of inhalant-induced psychotic symptoms without further specification.

Treatment Options

Treatment typically includes cessation of inhalant use, often supported by behavioral therapies (e.g., cognitive-behavioral therapy) and, if needed, pharmacotherapy to manage withdrawal or psychotic symptoms. Supportive care addresses physical and psychological effects, and long-term recovery may involve counseling or rehabilitation programs. Individualized plans are tailored to the patient's needs.

Prognosis and Follow-Up

Prognosis depends on the severity of use, duration of symptoms, and response to treatment. Early intervention improves outcomes, but chronic use may lead to persistent cognitive or psychiatric issues. Follow-up care includes monitoring for relapse, managing co-occurring disorders, and providing ongoing support to maintain abstinence and functional recovery.

Complications

• Persistent cognitive impairment (e.g., memory loss, attention deficits).
• Worsening of psychotic symptoms or development of chronic psychotic disorders.
• Physical harm from inhalant toxicity (e.g., organ damage, neurological deficits).
• Increased risk of accidents or injuries due to impaired judgment.
• Social or occupational dysfunction.

Lifestyle & Prevention

• Avoiding access to inhalant products, especially for at-risk individuals.
• Educating communities about the dangers of inhalant misuse.
• Promoting healthy coping mechanisms and stress management.
• Encouraging open communication about substance use.
• Supporting environments that reduce peer pressure or experimentation.

When to Seek Professional Help

Seek immediate medical attention if experiencing severe psychotic symptoms, signs of inhalant overdose (e.g., respiratory distress), or if unable to stop using inhalants. Professional help is also recommended for persistent cravings, worsening mental health, or if inhalant use interferes with daily life.

Tips for Medical Coders

Document the presence of inhalant abuse and inhalant-induced psychotic symptoms without further specification. Ensure clinical notes clearly link psychotic features to inhalant use and specify the absence of delusions or hallucinations as separate qualifiers. Code F18.159 is appropriate when psychotic symptoms are present but not categorized as delusions or hallucinations. Verify documentation supports the unspecified nature of the psychotic disorder.